TriangleNCT04467697 · OUTCOME
Observed and Change From Baseline in Serum Prostate-specific Antigen (PSA) in SOV2012-F1 Treated Subjects During the Treatment Period.
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- ng/mL
- Interval / dispersion
- Standard Deviation
- Time frame
- 90 and 180 days
What was measured
Serum prostate-specific antigen (PSA) in SOV2012-F1 treated subjects were assessed during the treatment period, measurement units of ng/mL.
Analysis population: Extension Treated Set
Groups in this outcome
SOV2012-F1-treated, Observed
Patients treated with SOV2012-F1, starting daily dose in MRS-TU-2019EXT is 400 mg - (200 mg with morning meal and 200 mg with evening meal). Dosing is titrated up to a maximum of 800 mg SOV2012-F1 per day (400 mg in the morning with morning meal and 400 mg in the evening with evening meal) or down to a minimum of 100 mg SOV2012-F1 per day (100 mg with morning meal) based on plasma T after 14 and 42 days of treatment. Patients could be titrated to final daily dose levels of 100 mg, 200 mg (100 mg twice daily), 400 mg (200 mg twice daily), 600 mg (300 mg twice daily) or 800 mg (400 mg twice daily). All doses taken with meals. SOV2012-F1: oral preparation of testosterone undecanoate (TU) in 100 mg, 150 mg and 200 mg strengths.
SOV2012-F1-treated, Change From Baseline
Patients treated with SOV2012-F1, starting daily dose in MRS-TU-2019EXT is 400 mg - (200 mg with morning meal and 200 mg with evening meal). Dosing is titrated up to a maximum of 800 mg SOV2012-F1 per day (400 mg in the morning with morning meal and 400 mg in the evening with evening meal) or down to a minimum of 100 mg SOV2012-F1 per day (100 mg with morning meal) based on plasma T after 14 and 42 days of treatment. Patients could be titrated to final daily dose levels of 100 mg, 200 mg (100 mg twice daily), 400 mg (200 mg twice daily), 600 mg (300 mg twice daily) or 800 mg (400 mg twice daily). All doses taken with meals. SOV2012-F1: oral preparation of testosterone undecanoate (TU) in 100 mg, 150 mg and 200 mg strengths.
| Group | Source count |
|---|---|
| SOV2012-F1-treated, Observed | 155 |
| SOV2012-F1-treated, Change From Baseline | 155 |
Reported measurements
Prostate Specific Antigen, Baseline
| Group | Source count |
|---|---|
| SOV2012-F1-treated, Observed | 155 |
| SOV2012-F1-treated, Change From Baseline | 155 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| SOV2012-F1-treated, Observed | 0.98 | 0.651 | Not reported | Not reported | Not reported |
| SOV2012-F1-treated, Change From Baseline | 0 | 0 | Not reported | Not reported | Not reported |
Prostate Specific Antigen, Visit 12E - Day 90E
| Group | Source count |
|---|---|
| SOV2012-F1-treated, Observed | 143 |
| SOV2012-F1-treated, Change From Baseline | 143 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| SOV2012-F1-treated, Observed | 1.10 | 0.719 | Not reported | Not reported | Not reported |
| SOV2012-F1-treated, Change From Baseline | 0.15 | 0.309 | Not reported | Not reported | Not reported |
Prostate Specific Antigen, Visit 16E - EOT Day 180E
| Group | Source count |
|---|---|
| SOV2012-F1-treated, Observed | 135 |
| SOV2012-F1-treated, Change From Baseline | 135 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| SOV2012-F1-treated, Observed | 1.09 | 0.743 | Not reported | Not reported | Not reported |
| SOV2012-F1-treated, Change From Baseline | 0.15 | 0.443 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 0.651
- value
- 0.98
- group Id
- OG001
- spread
- 0
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 155
- group Id
- OG001
- value
- 155
- units
- Participants
- title
- Prostate Specific Antigen, Baseline
- categories
- measurements
- group Id
- OG000
- spread
- 0.719
- value
- 1.10
- group Id
- OG001
- spread
- 0.309
- value
- 0.15
- denoms
- counts
- group Id
- OG000
- value
- 143
- group Id
- OG001
- value
- 143
- units
- Participants
- title
- Prostate Specific Antigen, Visit 12E - Day 90E
- categories
- measurements
- group Id
- OG000
- spread
- 0.743
- value
- 1.09
- group Id
- OG001
- spread
- 0.443
- value
- 0.15
- denoms
- counts
- group Id
- OG000
- value
- 135
- group Id
- OG001
- value
- 135
- units
- Participants
- title
- Prostate Specific Antigen, Visit 16E - EOT Day 180E
- denoms
- counts
- group Id
- OG000
- value
- 155
- group Id
- OG001
- value
- 155
- units
- Participants
- description
- Serum prostate-specific antigen (PSA) in SOV2012-F1 treated subjects were assessed during the treatment period, measurement units of ng/mL.
- dispersion Type
- Standard Deviation
- groups
- description
- Patients treated with SOV2012-F1, starting daily dose in MRS-TU-2019EXT is 400 mg - (200 mg with morning meal and 200 mg with evening meal). Dosing is titrated up to a maximum of 800 mg SOV2012-F1 per day (400 mg in the morning with morning meal and 400 mg in the evening with evening meal) or down to a minimum of 100 mg SOV2012-F1 per day (100 mg with morning meal) based on plasma T after 14 and 42 days of treatment. Patients could be titrated to final daily dose levels of 100 mg, 200 mg (100 mg twice daily), 400 mg (200 mg twice daily), 600 mg (300 mg twice daily) or 800 mg (400 mg twice daily). All doses taken with meals. SOV2012-F1: oral preparation of testosterone undecanoate (TU) in 100 mg, 150 mg and 200 mg strengths.
- id
- OG000
- title
- SOV2012-F1-treated, Observed
- description
- Patients treated with SOV2012-F1, starting daily dose in MRS-TU-2019EXT is 400 mg - (200 mg with morning meal and 200 mg with evening meal). Dosing is titrated up to a maximum of 800 mg SOV2012-F1 per day (400 mg in the morning with morning meal and 400 mg in the evening with evening meal) or down to a minimum of 100 mg SOV2012-F1 per day (100 mg with morning meal) based on plasma T after 14 and 42 days of treatment. Patients could be titrated to final daily dose levels of 100 mg, 200 mg (100 mg twice daily), 400 mg (200 mg twice daily), 600 mg (300 mg twice daily) or 800 mg (400 mg twice daily). All doses taken with meals. SOV2012-F1: oral preparation of testosterone undecanoate (TU) in 100 mg, 150 mg and 200 mg strengths.
- id
- OG001
- title
- SOV2012-F1-treated, Change From Baseline
- param Type
- MEAN
- population Description
- Extension Treated Set
- reporting Status
- POSTED
- time Frame
- 90 and 180 days
- title
- Observed and Change From Baseline in Serum Prostate-specific Antigen (PSA) in SOV2012-F1 Treated Subjects During the Treatment Period.
- type
- OTHER_PRE_SPECIFIED
- unit Of Measure
- ng/mL
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice